Therapy

Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Retrieved on: 
Tuesday, May 17, 2022
Phenotype, CRPC, BTK, Pain, Risk, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Postherpetic neuralgia, TKI, SNP, Patient, RPF, PHN, Vaccine, Antibody, Bone, RECIST, Phase, Therapy, MCRPC, Trial of the century, FDA, SAN, IND, Partnership, Prostate cancer, Toxicity, Osteoarthritis, Autoimmune disease, Safety, Forward-looking statement, HSD3B1, EGFR, TRPV1, Phosphorylation, CAGR, RTX, Cancer, Castration, Sciatica, Security (finance), Neoplasm, Annual report, GLOBE, Pharmaceutical industry, Pet, Generic drug, COVID-19

FDA granted IND clearance for Abivertinib (Fujovee) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.

Key Points: 
  • FDA granted IND clearance for Abivertinib (Fujovee) for the Phase 2 MAVERICK study to be conducted in participants with metastatic castrate resistant prostate cancer (mCRPC) at multiple centers in the United States.
  • The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-nave and abiraterone-progressing mCRPC.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.
  • RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients.

New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy

Retrieved on: 
Tuesday, May 17, 2022
STIM, Advanced Diagnostic Ultrasound in Microgravity, Lists of diseases, MDD, R, Ageing, Brain Stimulation (journal), Patient Health Questionnaire, VP, Transcranial magnetic stimulation, Patient, NASDAQ, SBL, Quality of life, Therapy, Advanced Therapy Medicinal Product, Depression, LUL, Marketing, Institute, FDA, Industry, OCD, TMS, Safety, Mental health, Neuroscience, Diagnosis, GLOBE, Pharmaceutical industry, Neuronetics

MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, announced today a new peer-reviewed paper, published in Brain Stimulation Journal and available online now. The paper compares clinical outcomes of patients who received NeuroStar TMS through either high frequency left unilateral TMS (HF-LUL) or sequential bilateral treatment (SBL) TMS throughout their treatment course.

Key Points: 
  • We are happy to continue sharing data insights from the largest outcomes registry database in TMS to provide clinicians new evidence to inform their treatment decisions, stated Cory Anderson, VP, R&D and Clinical.
  • The clinical insights we continue to attain from NeuroStars large, proprietary dataset allow us to identify and refine best practices for treatment with NeuroStar TMS.
  • To learn more about NeuroStar Advanced Therapy, including prescribing and safety information, visit www.neurostar.com .
  • NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the worlds largest depression Outcomes Registry.

Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 17, 2022
Company, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, Nature, Lists of diseases, Securities Act of 1933, Securities Exchange Act of 1934, Industry, Conference, Central nervous system, Therapy, United, Risk management, Pharmaceutical industry

Please contact your representative at H.C. Wainwright to schedule an in-person or virtual one-on-one meeting with Reviva Pharmaceuticals during the respective conference.

Key Points: 
  • Please contact your representative at H.C. Wainwright to schedule an in-person or virtual one-on-one meeting with Reviva Pharmaceuticals during the respective conference.
  • For information about the H.C. Wainwright Global Investment Conference, please refer to the events website .
  • Revivais a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families.
  • The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Retrieved on: 
Tuesday, May 17, 2022
Legal, Professional Services, Chemistry, Company, U.S. Securities and Exchange Commission, Certification, Ethics, NASDAQ, Therapy, Complaint, FDA, CMC, Securities Exchange Act of 1934, Suite, SEC Rule 10b-5, NDA, Security (finance)

Investors who purchased the Company's securities between December 30, 2019 and April 22, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before July 12, 2022.

Key Points: 
  • Investors who purchased the Company's securities between December 30, 2019 and April 22, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before July 12, 2022.
  • If you are a shareholder who suffered a loss, click here to participate .
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

Retrieved on: 
Tuesday, May 17, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Company, Research, Degenerative disease, Infection, Lists of diseases, Technology, Conference, Euronext Paris, APM, Therapy, SEC, JT Group Limited, Prospectus, Pharmaceutical industry, EU, Science

Aptorum Group management will be available and conducting online one-on-one meetings with institutional investors through the conference.

Key Points: 
  • Aptorum Group management will be available and conducting online one-on-one meetings with institutional investors through the conference.
  • The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g.
  • This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.
  • Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

Retrieved on: 
Tuesday, May 17, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Death, Niemann–Pick disease, CytRx, Idiopathic hypersomnia, ImmunityBio, Annual report, Doctor of Philosophy, Neurodegeneration, Patient, Lipid, Nature, USD, CRL, Research, FDA, CNS, Cholesterol, Forward-looking statement, EMA, Central nervous system, NPC, NDA, Arimoclomol, Therapy, Acquisition, SEC, Cancer, OTCQB, Pharmaceutical industry

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (KemPharm).

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. (KemPharm).
  • Under the terms of the agreement, KemPharm will purchase substantially all of the assets and operations of Orphazyme, including arimoclomol, for a cash payment of USD $12.8 million.
  • CytRx licensed arimoclomol to Orphazyme for milestones and royalties on sales, and CytRx expects the terms of its license with Orphazyme to remain intact as the arimoclomol asset transfers to KemPharm.
  • All forward-looking statements are based upon information available to the CytRx on the date the statements are first published.

Equillium to Present at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 17, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Risk, Itolizumab, Private Securities Litigation Reform Act, EDGAR, Patient, Event, Feedback, Trial of the century, Volunteering, Degenerative disease, Alopecia areata, Forward-looking statement, Safety, Therapy, Acquisition, SEC, Pharmaceutical industry

An archived replay of both conferences will be available for 90 days.

Key Points: 
  • An archived replay of both conferences will be available for 90 days.
  • Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need.
  • The companys pipeline consists of the following novel immunomodulatory assets targeting immuno-inflammatory pathways.
  • Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022

Retrieved on: 
Tuesday, May 17, 2022
Biotechnology, Pharmaceutical, Alternative Medicine, Finance, General Health, Health, Mental Health, Professional Services, Engineering, Company, Regulation of tobacco by the U.S. Food and Drug Administration, Disease, Food, U.S. Securities and Exchange Commission, EDGAR, Lists of diseases, New, News, Patient, Goal, View, Psilocybin, Therapy, COVID-19, Inc., Research, United Kingdom, NYSE American, Time, NEO, Forward-looking statement, Safety, Risk, Health Canada, Growth, NYSE, Pharmaceutical industry

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM is pleased to announce that it will participate in the morning trading bell ceremony on May 18, 2022 at the New York Stock Exchange (NYSE) in New York City.

Key Points: 
  • Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM is pleased to announce that it will participate in the morning trading bell ceremony on May 18, 2022 at the New York Stock Exchange (NYSE) in New York City.
  • Cybin, whose shares commenced trading on the NYSE American on August 5, 2021, was the first psychedelics company to be listed on the NYSE.
  • We are delighted to be part of this ceremony as we celebrate the innovation that Cybin is bringing to the challenges of mental health treatments today.
  • If you would like to schedule a meeting, please contact Cybin Investor Relations at [email protected] or call 917-543-9932.

Women-led Early Stage VC with Three Unicorns in First Fund Announces Over-subscribed Third Fund

Retrieved on: 
Tuesday, May 17, 2022
Finance, Banking, Women, Consumer, Professional Services, Growth capital, Doctor of Philosophy, Partner, Investment, Woman, Goal, Therapy, Mercedes de Lasala de Riglos, App Store (iOS/iPadOS), Republic, Female, Good, Apple, Drug discovery, UNSDG, ESG, Financial services, Cryptocurrency, Pharmaceutical industry

The majority women- and minority-owned firm is known for investing early in complex technologies that are yielding top returns.

Key Points: 
  • The majority women- and minority-owned firm is known for investing early in complex technologies that are yielding top returns.
  • Good Growth Capitals first fund, a 2017 vintage, is tracking to earn top-decile returns.
  • This new fund makes Good Growth Capital the largest venture capital fund in South Carolina history and one of the largest early-stage funds in the Southeast.
  • Good Growth Capital invests in pre-seed through Series B investments in biomedical and health sciences, green tech, data, and physical and material sciences.

Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022

Retrieved on: 
Tuesday, May 17, 2022
General Health, Diabetes, Health, Science, Other Science, Disease, Glucose, Patient, Health, DMR, Diabetes, Lists of diseases, Mortality, FDA, GIP, Type 2 diabetes, Insulin, Glucagon, Therapy, CA, Medical device, Pharmaceutical industry, T2D

Fractyl Health , an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Disease Week meeting being held May 21-24, 2022, in San Diego, CA.

Key Points: 
  • Fractyl Health , an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Disease Week meeting being held May 21-24, 2022, in San Diego, CA.
  • Data being presented reflect changes in glucoregulatory hormones and insulin sensitivity in patients with type 2 diabetes after treatment with Revita Duodenal Mucosa Resurfacing (DMR), an endoscopic procedure using hydrothermal energy to ablate and regenerate duodenal mucosa.
  • The analysis was performed using data from the companys Revita-1 and Revita-2 clinical studies.
  • Revita has received a CE mark in Europe and in January 2022 received reimbursement authorization in Germany.